These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28926467)

  • 1. A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis.
    Bilal J; Riaz IB; Kamal MU; Elyan M; Sudano D; Khan MA
    J Clin Rheumatol; 2018 Jan; 24(1):6-13. PubMed ID: 28926467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis.
    Mourad A; Gniadecki R
    J Rheumatol; 2020 Jan; 47(1):59-65. PubMed ID: 30824641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
    Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
    J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.
    Lu C; Wallace BI; Waljee AK; Fu W; Zhang Q; Liu Y
    Semin Arthritis Rheum; 2019 Dec; 49(3):381-388. PubMed ID: 31272807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
    Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
    Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of biologics targeting interleukin-6, -12/23 and -17 pathways for peripheral psoriatic arthritis: a network meta-analysis.
    Wu D; Yue J; Tam LS
    Rheumatology (Oxford); 2018 Mar; 57(3):563-571. PubMed ID: 29244162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis.
    Song GG; Lee YH
    Z Rheumatol; 2018 Sep; 77(7):613-620. PubMed ID: 28791450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Dahal K; Sharma S
    Rheumatol Int; 2016 Aug; 36(8):1065-75. PubMed ID: 27105880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: A combined and updated meta-analysis.
    He C; Xue C; Zhu G; Kang P
    J Clin Pharm Ther; 2021 Aug; 46(4):895-906. PubMed ID: 33768576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations.
    Maharaj AB; Chandran V
    Expert Rev Clin Immunol; 2017 Apr; 13(4):319-331. PubMed ID: 27826996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.
    Genovese MC; Greenwald M; Cho CS; Berman A; Jin L; Cameron GS; Benichou O; Xie L; Braun D; Berclaz PY; Banerjee S
    Arthritis Rheumatol; 2014 Jul; 66(7):1693-704. PubMed ID: 24623718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.
    Mease PJ; Gottlieb AB; Berman A; Drescher E; Xing J; Wong R; Banerjee S
    Arthritis Rheumatol; 2016 Sep; 68(9):2163-73. PubMed ID: 27059799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review.
    Sondag M; Verhoeven F; Guillot X; Prati C; Wendling D
    Clin Rheumatol; 2019 Feb; 38(2):591-596. PubMed ID: 30328022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
    Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
    N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does previous use of tumour necrosis inhibitors change the therapeutic effect of interleukin (IL)-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis? Results of a systematic review.
    Xie Y; Liu Y
    Clin Exp Dermatol; 2022 Sep; 47(9):1627-1635. PubMed ID: 35466472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
    Speeckaert R; van Geel N; Lambert J; Claeys L; Delanghe JR; Speeckaert MM
    Drugs Today (Barc); 2016 Nov; 52(11):607-616. PubMed ID: 28112279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
    Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
    Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of IL-17 inhibitors for patients with psoriatic arthritis: a systematic review and meta-analysis.
    Gao Q; Zhao YX; Wang XJ; Shi J; Wang HM
    Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2958-2970. PubMed ID: 33877659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.